PERSPECTA

News from every angle

← Back to headlines

SciSparc Stock Surges on NeuroThera's CliniQuantum Deal Approval

SciSparc's stock more than doubled after NeuroThera received conditional approval for its CliniQuantum deal, signaling a significant market reaction.

28 May, 16:53 — 28 May, 16:53
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed95d ago

SciSparc more than doubles as NeuroThera wins conditional nod for CliniQuantum deal

Read full article →

Related Stories

Shein Shares Drop in Disappointing Hong Kong Stock Market Debut

15m ago

Japanese Corporations Increase Capital Spending Amid Profit Surge

36m ago

Baidu Completes Conversion to Dual-Primary Hong Kong Listing

54m ago

South Korea Unveils Record 2027 Budget Focused on AI and Defense Spending

1h ago